Oral Chronic Graft Versus Host Disease (cGVHD) is a frequent and serious complication following stem cell transplant. Researchers at NIH are evaluating the safety and efficacy of topical dexamethasone solution used as an oral rinse for prevention of oral cGVHD. This research study will provide valuable insights into the causes and development of oral cGVHD and potentially lead to new treatment strategies.

Who can participate?
- Stem cell recipients ages 18 years and older
- Patients that have undergone a recent allogenic hematopoietic stem cell transplant
- Ability to rinse with study medication (dexamethasone) or placebo
- Ability and willingness to come to NIH Clinical Center in Bethesda, MD for follow-up appointments

Study design:
- Review of medical history and oral examination
- Intervention with dexamethasone or placebo oral rinse
- Quality of Life Questionnaires
- Study-related tests, procedures and medications provided at no cost

Location: The NIH Clinical Center, America’s Research Hospital is located on the Metro red line (Medical Center stop) in Bethesda, Maryland.

For more information call:
NIH Clinical Center Office of Patient Recruitment
1- 800 - 411-1222 (refer to study 07-H-0005)
TTY for the deaf or hard of hearing:1-866-411-1010
https://go.usa.gov/xnhak
prpl@cc.nih.gov